Title: Vorapaxar in atherosclerotic disease management.
Journal: The Annals of pharmacotherapy20150501
Title: Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.
Journal: The American journal of cardiology20150415
Title: Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
Journal: European journal of clinical pharmacology20121101
Title: Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
Journal: Lancet (London, England)20121013
Title: Platelet protease-activated receptor antagonism in cardiovascular medicine.
Journal: Coronary artery disease20120901
Title: Developing PAR1 antagonists: minding the endothelial gap.
Journal: Discovery medicine20120601
Title: Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Journal: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association20120501
Title: Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Journal: Expert review of cardiovascular therapy20120301
Title: Promises of PAR-1 inhibition in acute coronary syndrome.
Journal: Current cardiology reports20120201
Title: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Journal: The New England journal of medicine20120105
Title: Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Journal: Hamostaseologie20120101
Title: Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
Journal: Advances in cardiology20120101
Title: PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis.
Journal: Handbook of experimental pharmacology20120101
Title: Vorapaxar: a novel protease-activated receptor-1 inhibitor.
Journal: Expert opinion on investigational drugs20111001
Title: Antiplatelet therapy: thrombin receptor antagonists.
Journal: British journal of clinical pharmacology20111001
Title: Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Journal: American heart journal20110301
Title: Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Journal: Drug metabolism and disposition: the biological fate of chemicals20110101
Title: Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
Journal: Expert opinion on investigational drugs20101201
Title: Discovery of a vorapaxar analog with increased aqueous solubility.
Journal: Bioorganic & medicinal chemistry letters20101115
Title: Challenges and promises of developing thrombin receptor antagonists.
Journal: Recent patents on cardiovascular drug discovery20101101
Title: Emerging oral antiplatelet therapies for acute coronary syndromes.
Journal: Hospital practice (1995)20101101
Title: Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Journal: Journal of cellular and molecular medicine20101001
Title: Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.
Journal: Drugs20101001
Title: Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Journal: Expert review of cardiovascular therapy20100801
Title: [Novel agents in antiplatelet therapy].
Journal: Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir20100701
Title: Molecular Medicine - CHI's 17th International Tri-Conference: Mastering Medicinal Chemistry - CHI's Seventh Annual Conference.
Journal: IDrugs : the investigational drugs journal20100401
Title: Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Journal: Journal of atherosclerosis and thrombosis20100226
Title: Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.
Journal: British journal of pharmacology20100201
Title: Platelet thrombin receptor antagonism and atherothrombosis.
Journal: European heart journal20100101
Title: New antiplatelet agents: why they are needed.
Journal: European journal of internal medicine20091201
Title: Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Journal: Medical science monitor : international medical journal of experimental and clinical research20091201
Title: Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets.
Journal: British journal of pharmacology20091101
Title: Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
Journal: Hamostaseologie20091101
Title: SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
Journal: Current opinion in investigational drugs (London, England : 2000)20090901
Title: SCH 530348: a novel oral thrombin receptor antagonist.
Journal: Future cardiology20090901
Title: New antiplatelet drugs: beyond aspirin and clopidogrel.
Journal: International journal of clinical practice20090501
Title: The ischaemia/bleeding balance in PCI.
Journal: Lancet (London, England)20090314
Title: Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Journal: Lancet (London, England)20090314
Title: Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases.
Journal: Recent patents on cardiovascular drug discovery20090101
Title: Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions20090101
Title: Advances in antiplatelet therapy for ACS and PCI.
Journal: Journal of interventional cardiology20081201
Title: Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
Journal: Journal of pharmacological sciences20081201
Title: Pharmacology of emerging novel platelet inhibitors.
Journal: American heart journal20080801
Title: Clinical overview of promising nonthienopyridine antiplatelet agents.
Journal: American heart journal20080801
Title: Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
Journal: Journal of medicinal chemistry20080612
Title: Khoufache K, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123(1):206-14.
Title: Kehinde O, et al. Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105.
